AU2002367023A1 - Compositions and methods for treating heart failure - Google Patents

Compositions and methods for treating heart failure

Info

Publication number
AU2002367023A1
AU2002367023A1 AU2002367023A AU2002367023A AU2002367023A1 AU 2002367023 A1 AU2002367023 A1 AU 2002367023A1 AU 2002367023 A AU2002367023 A AU 2002367023A AU 2002367023 A AU2002367023 A AU 2002367023A AU 2002367023 A1 AU2002367023 A1 AU 2002367023A1
Authority
AU
Australia
Prior art keywords
compositions
methods
heart failure
treating heart
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002367023A
Other languages
English (en)
Other versions
AU2002367023A8 (en
Inventor
Kathleen Elias
Bainian Feng
Erica Anne Kraynack
Pu-Ping Lu
Fady Malik
David J. Morgans Jr.
Xiangping Qian
Whitney Walter Smith
Adam Lewis Tomasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AU2002367023A1 publication Critical patent/AU2002367023A1/en
Publication of AU2002367023A8 publication Critical patent/AU2002367023A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2002367023A 2001-12-21 2002-12-20 Compositions and methods for treating heart failure Abandoned AU2002367023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34308801P 2001-12-21 2001-12-21
US60/343,088 2001-12-21
PCT/US2002/040996 WO2003059258A2 (en) 2001-12-21 2002-12-20 Compositions and methods for treating heart failure

Publications (2)

Publication Number Publication Date
AU2002367023A1 true AU2002367023A1 (en) 2003-07-30
AU2002367023A8 AU2002367023A8 (en) 2003-07-30

Family

ID=23344654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002367023A Abandoned AU2002367023A1 (en) 2001-12-21 2002-12-20 Compositions and methods for treating heart failure

Country Status (6)

Country Link
US (3) US6908923B2 (https=)
EP (1) EP1503986B1 (https=)
JP (2) JP4361800B2 (https=)
AU (1) AU2002367023A1 (https=)
CA (1) CA2470427C (https=)
WO (1) WO2003059258A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495337B1 (en) * 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
EP1503986B1 (en) 2001-12-21 2015-09-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
DK1789390T3 (da) 2004-09-02 2012-02-27 Genentech Inc Pyridyl-inhibitorer af hedgehog-signalering
CA2584185C (en) * 2004-10-13 2014-07-15 Frank Stieber Heterocyclic substituted bisarylurea derivates as kinase inhibitors
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
CA2774515A1 (en) * 2009-09-17 2011-03-24 Vanderbilt University Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
AU2018332887B2 (en) 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
TW202315628A (zh) * 2021-06-24 2023-04-16 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055905A (en) 1958-03-04 1962-09-25 Geigy Chem Corp New sulphamyl benzamides
US3447922A (en) * 1964-12-28 1969-06-03 Xerox Corp Electrically photosensitive particles useful in photoelectrophoretic and xerographic imaging processes
US3577550A (en) * 1968-05-02 1971-05-04 Dow Chemical Co N-(phenoxy)phenyl-salicylamides and their utilization as molluscidides
US3674850A (en) * 1969-12-07 1972-07-04 Lever Brothers Ltd Substituted salicylanilides
DE2248662A1 (de) * 1972-10-04 1974-04-18 Bayer Ag Loesliche aromatische copolyamide und daraus hergestellte faeden mit hohem elastizitaetsmodul und hoher reissfestigkeit
DE3139457A1 (de) 1981-10-03 1983-04-21 Bayer Ag, 5090 Leverkusen Neue substituierte benzanilidether, verfahren zu ihrer herstellung, ihre verwendung als fungizide und zwischenprodukte hierfuer
FR2601015B1 (fr) 1986-07-04 1988-08-05 Rhone Poulenc Sante Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH02115839A (ja) 1988-10-26 1990-04-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー感光材料
JPH0717594B2 (ja) 1989-01-25 1995-03-01 久光製薬株式会社 新規なスルホンアニリド誘導体
JP2795519B2 (ja) 1990-04-11 1998-09-10 三井化学株式会社 芳香族ポリアミド
JP2821564B2 (ja) 1991-05-29 1998-11-05 住化ファインケム株式会社 キナゾリノン誘導体の製造方法
FR2687574B1 (fr) 1992-02-25 1995-05-05 Rhone Poulenc Rorer Sa Nouvelle application therapeutique de derives du pyridylpyrrolothiazole carboxamide.
WO1994022830A1 (en) * 1993-03-31 1994-10-13 Smithkline Beecham Corporation Chemical compounds
US6001379A (en) 1993-09-15 1999-12-14 L'oreal Stable acidic oil-in- water type emulsions and compositions containing them
CZ61098A3 (cs) 1995-08-30 1998-06-17 Bayer Aktiengesellschaft Amidy kyseliny acylaminosalicylové jako prostředky pro potírání škůdců, způsob jejich výroby a meziprodukty pro jejich výrobu
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
US6143472A (en) * 1998-11-18 2000-11-07 Wako Pure Chemical Industries, Ltd. Resist composition and a method for formation of a pattern using the composition
AR015514A1 (es) * 1998-02-10 2001-05-02 Novartis Ag Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene
GB9822238D0 (en) 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
US6410254B1 (en) * 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6521622B1 (en) 1999-07-20 2003-02-18 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
CN1237051C (zh) 1999-08-20 2006-01-18 道农业科学公司 杀真菌的杂环芳族酰胺和它们的组合物、使用方法和制备
DE10010002A1 (de) 2000-03-02 2001-09-06 Celanese Ventures Gmbh Verfahren zur Nitrierung und Aminierung von Arylpolymer
US6495337B1 (en) * 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
DE10110002B4 (de) 2001-03-01 2006-03-09 Georg Oswald Lange Toilettensitz
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2003037900A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
EP1503986B1 (en) 2001-12-21 2015-09-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
EP1535609A4 (en) * 2002-06-10 2009-01-07 Inst Med Molecular Design Inc Nf-kb activation inhibitors
EA010835B1 (ru) 2002-06-10 2008-12-30 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения рака
CA2488979A1 (en) 2002-06-11 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
EP1503986B1 (en) 2015-09-30
EP1503986A4 (en) 2005-11-30
EP1503986A2 (en) 2005-02-09
US7605164B2 (en) 2009-10-20
CA2470427A1 (en) 2003-07-24
US7053094B2 (en) 2006-05-30
US20030158233A1 (en) 2003-08-21
US20050148638A1 (en) 2005-07-07
JP2005514432A (ja) 2005-05-19
AU2002367023A8 (en) 2003-07-30
US20060173024A1 (en) 2006-08-03
CA2470427C (en) 2012-07-10
US6908923B2 (en) 2005-06-21
WO2003059258A2 (en) 2003-07-24
JP4361800B2 (ja) 2009-11-11
WO2003059258A3 (en) 2004-11-11
JP2005068160A (ja) 2005-03-17

Similar Documents

Publication Publication Date Title
AU2001249881A1 (en) Method of treating the heart
AU2002254158A1 (en) Medical devices, compositions and methods for treating vulnerable plaque
AU2002367023A1 (en) Compositions and methods for treating heart failure
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
AU2002365057A1 (en) Compositions and methods for treating heart failure
AU2003212850A1 (en) Methods and compositions for treating cardiovascular disease
AU2003232115A1 (en) Methods and compositions for the treatment of graft failure
AUPR731901A0 (en) Method of treatment
AU2003259202A1 (en) Compositions and methods for treating and preventing infection
AU2002245510A1 (en) Method and composition for embalming
AU2002364679A1 (en) Method and compositions for treating respiratory pathologies
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2003275433A1 (en) Compositions and methods for treating pain
AU2002342188A1 (en) Methods and compositions for treating flavivirus-mediated disease
AU2002353915A1 (en) Methods and compositions for treating rotavirus-mediated disease
AU2002246221A1 (en) Method and composition
AU2003214606A1 (en) Compositions and methods for treating mdma-induced toxicity
AU2002307034A1 (en) Compositions and methods for diagnosing or treating psoriasis
AU2002340589A1 (en) Treating composition
AU2002333144A1 (en) Compositions and methods for selected tumor treatment
AU2002342195A1 (en) Method and composition for treating wood
AU2002309976A1 (en) Composition and method for the treatment of pigmentation disorders
AU2002305613A1 (en) Methods and compositions for treat lung diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase